Actinium Pharmaceuticals Inc (ATNM) - Net Assets

Latest as of March 2026: $2.30 Million USD

Based on the latest financial reports, Actinium Pharmaceuticals Inc (ATNM) has net assets worth $2.30 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($45.44 Million) and total liabilities ($43.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Actinium Pharmaceuticals Inc (ATNM) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$2.30 Million
% of Total Assets	5.07%
Annual Growth Rate	N/A
5-Year Change	-89.35%
10-Year Change	-56.5%
Growth Volatility	303.97

Actinium Pharmaceuticals Inc - Net Assets Trend (2006–2025)

This chart illustrates how Actinium Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Actinium Pharmaceuticals Inc for the complete picture of this company's asset base.

Annual Net Assets for Actinium Pharmaceuticals Inc (2006–2025)

The table below shows the annual net assets of Actinium Pharmaceuticals Inc from 2006 to 2025. For live valuation and market cap data, see Actinium Pharmaceuticals Inc (ATNM) total market value.

Year	Net Assets	Change
2025-12-31	$7.83 Million	-76.09%
2024-12-31	$32.76 Million	-9.95%
2023-12-31	$36.38 Million	-45.28%
2022-12-31	$66.48 Million	-9.61%
2021-12-31	$73.55 Million	+19.94%
2020-12-31	$61.32 Million	+986.36%
2019-12-31	$5.64 Million	-35.95%
2018-12-31	$8.81 Million	-35.54%
2017-12-31	$13.67 Million	-24.08%
2016-12-31	$18.01 Million	-18.05%
2015-12-31	$21.97 Million	+1242.98%
2014-12-31	$-1.92 Million	-23.28%
2013-12-31	$-1.56 Million	-236.13%
2012-12-31	$1.15 Million	+1458.53%
2011-12-31	$-84.33K	+10.87%
2010-12-31	$-94.62K	+1.74%
2009-12-31	$-96.29K	-30.19%
2008-12-31	$-73.96K	-122.75%
2007-12-31	$-33.20K	-80.42%
2006-12-31	$-18.40K	--

Equity Component Analysis

This analysis shows how different components contribute to Actinium Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 40951916100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	$31.00K	0.40%
Other Comprehensive Income	$-20.00K	-0.26%
Other Components	$417.54 Million	5329.79%
Total Equity	$7.83 Million	100.00%

Actinium Pharmaceuticals Inc Competitors by Market Cap

The table below lists competitors of Actinium Pharmaceuticals Inc ranked by their market capitalization.

Company	Market Cap
Artea SA PA:ARTE	$37.03 Million
Microequities Asset Management Group Ltd AU:MAM	$37.03 Million
Brand 24 SA WAR:B24	$37.06 Million
Revoil S.A AT:REVOIL	$37.07 Million
Jin Yang Pharmaceutical Co. Ltd KQ:007370	$37.01 Million
Unisync Corp TO:UNI	$37.00 Million
INITECH Co. Ltd KQ:053350	$36.99 Million
GROUP PAREF INH. EO 25 F:G5I	$36.98 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Actinium Pharmaceuticals Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 32,758,000 to 7,834,000, a change of -24,924,000 (-76.1%).
Net loss of 33,887,000 reduced equity.
Other comprehensive income decreased equity by 20,000.
Other factors increased equity by 8,983,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	$-33.89 Million	-432.56%
Other Comprehensive Income	$-20.00K	-0.26%
Other Changes	$8.98 Million	+114.67%
Total Change	$-	-76.09%

Book Value vs Market Value Analysis

This analysis compares Actinium Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.70x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-12-31	$-0.24	$1.18	x
2007-12-31	$-0.09	$1.18	x
2008-12-31	$-0.20	$1.18	x
2009-12-31	$-0.26	$1.18	x
2010-12-31	$-0.25	$1.18	x
2011-12-31	$-3.16	$1.18	x
2012-12-31	$31.15	$1.18	x
2013-12-31	$-2.06	$1.18	x
2014-12-31	$-2.11	$1.18	x
2015-12-31	$17.28	$1.18	x
2016-12-31	$11.15	$1.18	x
2017-12-31	$6.14	$1.18	x
2018-12-31	$2.49	$1.18	x
2019-12-31	$1.13	$1.18	x
2020-12-31	$5.05	$1.18	x
2021-12-31	$3.58	$1.18	x
2022-12-31	$2.75	$1.18	x
2023-12-31	$1.37	$1.18	x
2024-12-31	$1.09	$1.18	x
2025-12-31	$0.25	$1.18	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Actinium Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -432.56%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -37652.22%
• Asset Turnover: 0.00x
• Equity Multiplier: 6.61x
Recent ROE (-432.56%) is below the historical average (-130.73%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	0.00%	0.00%	0.00x	0.00x	$-16.56K
2007	0.00%	0.00%	0.00x	0.00x	$-11.48K
2008	0.00%	0.00%	0.00x	0.00x	$-23.85K
2009	0.00%	0.00%	0.00x	0.00x	$-12.70K
2010	0.00%	0.00%	0.00x	0.00x	$11.14K
2011	0.00%	0.00%	0.00x	0.00x	$18.72K
2012	-729.81%	0.00%	0.00x	5.05x	$-8.48 Million
2013	0.00%	0.00%	0.00x	0.00x	$-10.62 Million
2014	0.00%	0.00%	0.00x	0.00x	$-24.50 Million
2015	-95.68%	0.00%	0.00x	1.21x	$-23.22 Million
2016	-135.06%	0.00%	0.00x	1.25x	$-26.12 Million
2017	-194.58%	0.00%	0.00x	1.34x	$-27.97 Million
2018	-268.41%	0.00%	0.00x	1.69x	$-24.54 Million
2019	-387.97%	0.00%	0.00x	2.07x	$-22.46 Million
2020	-36.23%	-3571.54%	0.01x	1.08x	$-28.35 Million
2021	-33.69%	-2165.56%	0.01x	1.09x	$-32.13 Million
2022	-49.66%	-3205.53%	0.01x	1.72x	$-39.67 Million
2023	-134.19%	-60269.14%	0.00x	2.24x	$-52.46 Million
2024	-116.74%	0.00%	0.00x	2.35x	$-41.52 Million
2025	-432.56%	-37652.22%	0.00x	6.61x	$-34.67 Million

Industry Comparison

This section compares Actinium Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $161,374,297
Average return on equity (ROE) among peers: -386.97%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Actinium Pharmaceuticals Inc (ATNM)	$2.30 Million	0.00%	18.72x	$37.02 Million
Aardvark Therapeutics, Inc. Common Stock (AARD)	$-54.64 Million	0.00%	0.00x	$98.20 Million
Abcellera Biologics Inc (ABCL)	$1.14 Billion	-12.83%	0.19x	$1.57 Billion
Abeona Therapeutics Inc (ABEO)	$681.00K	-3192.95%	12.43x	$313.99 Million
Acumen Pharmaceuticals Inc (ABOS)	$188.78 Million	-22.70%	0.04x	$179.85 Million
Abpro Holdings, Inc. (ABP)	$3.07 Million	-479.81%	1.57x	$2.00 Million
Absci Corp (ABSI)	$189.45 Million	-60.80%	0.14x	$793.56 Million
Arbutus Biopharma Corp (ABUS)	$26.88 Million	-30.41%	0.07x	$854.72 Million
ABVC Biopharma Inc (ABVC)	$-1.46 Million	0.00%	0.00x	$27.18 Million
Abivax SA American Depositary Shares (ABVX)	$34.66 Million	-45.66%	0.56x	$9.73 Billion
ACADIA Pharmaceuticals Inc (ACAD)	$84.98 Million	-24.53%	0.28x	$3.65 Billion

About Actinium Pharmaceuticals Inc

NYSE MKT:ATNM USA Biotechnology

Market Cap

$37.02 Million

Market Cap Rank

#23071 Global

#4914 in USA

Share Price

$1.18

Change (1 day)

+0.85%

52-Week Range

$0.98 - $1.94

All Time High

$102.00